Evaluation of the Long-term Safety, Tolerability, and Efficacy of Perampanel (E2007) as an Adjunctive Therapy in Levodopa Treated Parkinson's Disease Subjects With Motor Fluctuations

• ClinicalTrials.gov Identifier: NCT00505622
• Recruitment Status: Terminated
• First Posted: July 23, 2007
• Results First Posted: November 22, 2012
• Last Update Posted: January 21, 2016
• Sponsor: Eisai Limited
• Information provided by (Responsible Party): Eisai Inc. ( Eisai Limited )

Study Description

Brief Summary:

This is a multicentre, open-label extension study to evaluate the long-term safety, tolerability, and efficacy of Perampanel (E2007) as an adjunctive therapy in levodopa treated PD subjects with motor fluctuations. All subjects who have completed E2007-E044-213 or E2007-G000-309 will be candidates for entering this extension trial, provided that they meet the inclusion/exclusion criteria and have completed the core study, up to and including the final efficacy visit.

Condition or disease	Intervention/treatment	Phase
Parkinson's Disease	Drug: Perampanel	Phase 3

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 328 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Multi-centre, Open Label Extension Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Perampanel (E2007) as an Adjunctive Therapy in Levodopa Treated Parkinson's Disease Subjects With Motor Fluctuations
• Study Start Date: July 2007
• Actual Primary Completion Date: April 2008
• Actual Study Completion Date: April 2008

Arms and Interventions

Arm	Intervention/treatment
Experimental: E2007; E2007 2 mg (one 2 mg tablet taken daily in the evening), or 4 mg (two 2 mg tablets daily in the evening).	Drug: Perampanel

Outcome Measures

Primary Outcome Measures :

1. Mean Change From Baseline in Total Daily OFF Time (Hours) During Open-label Extension Study [ Time Frame: Baseline, Week 0, Week 2, Week 4, Week 8, Week 20, Follow-up ]
   OFF state is when medication has worn off and is no longer providing benefits with regard to stiffness, slowness, and tremor. All data was collected using a 3-day diary within a window of a defined visit.

Secondary Outcome Measures :

1. Mean Change From Baseline in UPDRS Part II (ADL) Score in OFF State (Hours) During Open-label Extension Study [ Time Frame: Baseline, Week 0, Week 20, Week 32 ]
   Unified Parkinson's Disease Rating Scale (UPDRS) is a standardized assessment of the symptoms and signs of Parkinson's Disease. Part II assesses activities of daily living (ADL) based on 13 items, such as speech, hygiene, and falling. Participants receive a score of 0-4 points per item, with a higher score indicating more severe symptoms. OFF state is when medication has worn off and is no longer providing benefits with regard to stiffness, slowness, and tremor.
2. Mean Change From Baseline in UPDRS Part III (Motor) Score in ON State (Hours) During Open-label Extension Study [ Time Frame: Baseline, Week 0, Week 20, Week 32 ]
   Unified Parkinson's Disease Rating Scale (UPDRS) is a standardized assessment of the symptoms and signs of Parkinson's Disease. Part III assesses motor activity, based on 14 items, such as gait, facial expression, and rigidity. Participants receive a score of 0-4 points per item, with a higher score indicating more severe symptoms. ON state is when medication is providing benefits to stiffness, slowness, and tremor.
3. Mean Change From Baseline in Total Daily ON Time (Without Dyskinesias or With Non-troublesome Dyskinesias) (Hours) During Open-label Extension Study [ Time Frame: Baseline, Week 0, Week 2, Week 4, Week 8, Week 20, Follow-up ]
   ON state is when medication is providing benefits with regard to stiffness, slowness, and tremor. All data was collected using a 3-day diary within a window of a defined visit.

Eligibility Criteria

• Ages Eligible for Study: 30 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

INCLUSION CRITERIA:

Male or female subjects with idiopathic PD who have fulfilled the entry criteria to studies E2007-G000-309 or E2007-E044-213.

Subjects must have completed the core efficacy study up to and including the final efficacy and follow up visits as applicable.

Subjects with mild or moderate AEs thought to be related to Perampanel (E2007) can be entered into the study if the investigator considers it safe.

EXCLUSION CRITERIA:

1. Show evidence of clinically significant disease (i.e., severe cardiovascular or pulmonary disease, bronchial asthma, endocrine disease, history of peptic ulcer disease, history of myocardial infarction with residual atrial nodal or ventricular arrhythmias) that, in the opinion of the investigator, could affect either the patient's safety or the conduct of the study.
2. Pregnant or lactating women.
3. Women of childbearing potential (WOCBP) unless infertile (including surgically sterile) or practicing effective contraception (e.g., intrauterine device [IUD] or barrier method plus hormonal method). These subjects must have a negative urine pregnancy test at Visit 1 or 2 as indicated by entry into the study. These subjects must also be willing to remain on their current form of contraception for the duration of the study. Postmenopausal women may be recruited but must be amenorrhoeic for at least 1 year to be considered of non-child bearing potential as determined by the investigator.
4. Subjects with a past (within the past 5 years) or present history of drug or alcohol abuse as per Diagnostic and Statistical Manual of Mental Disorders - Fourth Edition (DSM IV) criteria.
5. Antipsychotics are permitted as necessary. Subjects may be taking anti-depressant medication, however the dose must be stable for 4 weeks prior to their first study visit (the visit at which the inclusion and exclusion criteria are done with the patient).
6. Subjects with a past (within one year) or present history of major depression, suicidal ideation, or suicide attempts.
7. Subjects with unstable abnormalities of the hepatic, renal, cardiovascular, respiratory, gastrointestinal, haematological, endocrine, or metabolic systems that might complicate assessment of the tolerability of the study medication.
8. Subjects with significantly elevated liver enzymes (abnormal bilirubin or serum transaminase levels of more than 1.5 times the upper limit of the normal range).
9. Subjects with current or prior treatment (within 4 weeks prior to the Screening Visit) with medication known to induce the enzyme CYP3A4.
10. Clinically significant ECG abnormality, and/or prolonged QTc (defined as QTc ≥ 450 msec).
11. Current or prior treatment (within 4 weeks prior to entry visit) with tolcapone, methyldopa, budipine, or reserpine.
12. Subjects with previous stereotactic surgery (e.g., pallidotomy) for PD or with planned stereotactic surgery during the study period
13. Subjects receiving or with planned (next 12 months) deep brain stimulation.
14. Subjects with conditions affecting the peripheral or central sensory system unless related to PD (such as mild sensory or pain syndromes limited to OFF periods) that could interfere with the evaluation of any such symptoms caused by the study medication.
15. Subjects have received an investigational product (other than E2007 or entacapone 200 mg) within 4 weeks prior to Screening
16. Any condition that could, in the opinion of the investigator, place the subject at increased risk or is likely to prevent completion of the study.
17. Subjects with any condition that would make the subject, in the opinion of the investigator, unsuitable for the study.
18. Patients on pergolide or cabergoline.

Contacts and Locations

Locations

France

Centre d'Investigation Clinique, Hospital Purpan

Toulouse, Toulouse Cedex, France, 31059

Sponsors and Collaborators

Eisai Limited

Investigators

• Study Director: David Squillacote, MD; Eisai Inc.

More Information

• Responsible Party: Eisai Limited
• ClinicalTrials.gov Identifier: NCT00505622
• Other Study ID Numbers: E2007-G000-318; 2007-000801-30 ( EudraCT Number )
• First Posted: July 23, 2007
• Results First Posted: November 22, 2012
• Last Update Posted: January 21, 2016
• Last Verified: November 2015

Additional relevant MeSH terms:

Parkinson Disease; Parkinsonian Disorders; Basal Ganglia Diseases; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Movement Disorders; Synucleinopathies; Neurodegenerative Diseases